

Emetic Potential of Parenteral Chemo Agents

High: >90% risk; Mod: >30%-90% risk; Low: 10%-30% risk; Min: <10% risk

Drug	NCCN ¹	ASCO ²	MASCC/ ESMO ³
AC (anthracycline + cyclophosphamide)		high	
ado-trastuzumab emtansine		low	
aldesleukin	>12-15 million IU/m ² : mod ≤12 million IU/m ² : low	--	
alemtuzumab	min	mod	
amifostine	>300 mg/m ² : mod ≤300 mg/m ² : low	--	
amivantamab	low	--	
arsenic trioxide	low	mod	--
asparaginase	min	--	
atezolizumab	min		--
avelumab	min		--
axicabtagene ciloleucel	low ⁵		--
azacitidine	low		mod
belinostat		low	
bendamustine		mod	
bevacizumab (Alymsys , Avastin , Avzivi , Mvasi , Vegzelma , Zirabev)		min	
bleomycin		min	
blinatumomab	min		low
bortezomib	min		low
brentuximab vedotin		low	
brexucabtagene autoleucel	low ⁵		--
busulfan	mod		min
cabazitaxel		low	
carboplatin	AUC ≥4: high AUC <4: mod ⁴		mod

Drug	NCCN ¹	ASCO ²	MASCC/ ESMO ³
carfilzomib		low	
carmustine	>250 mg/m ² : high ≤250 mg/m ² : mod ⁴	high	
catumaxomab NUS	--	low	
cemiplimab	min		--
cetuximab	min	low	
ciltacabtagene autoleucl	low ⁵	--	
cisplatin		high	
cladribine		min	
clofarabine		mod	
copanlisib	low		--
cyclophosphamide	>1500 mg/m ² : high ≤1500 mg/m ² : mod ⁴	≥1500 mg/m ² : high <1500 mg/m ² : mod	
cytarabine	>200 mg/m ² : mod 100-200 mg/m ² : low <100 mg/m ² : min	>1000 mg/m ² : mod ≤1000 mg/m ² : low	
dacarbazine		high	
dactinomycin	mod ⁴	--	
daratumumab	min		--
daratumumab/hyaluronidase	min	--	
daunorubicin		mod ⁴	
daunorubicin/cytarabine liposomal	mod		--
decitabine	min	low	--
degarelix	min	--	
dexrazoxane	min	--	
dinutuximab	mod	--	
docetaxel		low	
dostarlimab	min	--	
doxorubicin	≥60 mg/m ² : high <60 mg/m ² : mod ⁴	mod	
doxorubicin liposomal		low	
durvalumab	min		--
elotuzumab	min	low	--

Drug	NCCN ¹	ASCO ²	MASCC/ ESMO ³
emapalumab	--	min	--
enfortumab vedotin	low		--
epcoritamab	min	--	
epirubicin	>90 mg/m ² : high ≤90 mg/m ² : mod ⁴	mod	
eribulin		low	
etoposide		low	
fam-trastuzumab deruxtecan	high	mod	--
floxuridine	low	--	
fludarabine		min	
5-fluorouracil (5-FU)		low	
fulvestrant	min	--	
gemcitabine		low	
gemtuzumab ozogamicin	low		--
glofitamab	min	--	
goserelin	min	--	
histrelin	min	--	
idarubicin		mod ⁴	
idecabtagene vicleucel	low ⁵	--	
ifosfamide	≥2 g/m ² /dose: high <2 g/m ² /dose: mod ⁴	mod	
inotuzumab ozogamicin	low		--
ipilimumab	min		low
irinotecan		mod ⁴	
irinotecan liposomal	mod		--
isatuximab	low	--	
ixabepilone		low	
lanreotide (Lanreotide , Somatuline Depot)	min	--	
leuprolide	min	--	
lisocabtagene maraleucel	low ⁵	--	
loncastuximab tesirine	low	--	
lurbinectedin	mod	--	
luspatercept	min	--	

Drug	NCCN ¹	ASCO ²	MASCC/ ESMO ³
margetuximab	min		--
mechlorethamine	high		--
melphalan	≥140 mg/m ² : high <140 mg/m ² : mod		--
methotrexate	≥250 mg/m ² : mod ⁴ >50- <250 mg/m ² : low ≤50 mg/m ² : min		low
mirvetuximab soravtansine	mod		--
mitomycin		low	
mitomycin pyelocalyceal	low		--
mitoxantrone		low	
mogamulizumab	low		--
mosunetuzumab	low		--
nab-paclitaxel	--		low
naxitamab	mod		--
necitumumab		low	--
nelarabine	min	low	--
nivolumab		min	
nivolumab/relatlimab	min		--
obinutuzumab		min	--
octreotide	min		--
ofatumumab		min	
omacetaxine mepesuccinate	low		--
oxaliplatin		mod ⁴	
paclitaxel		low	
paclitaxel nanoparticle albumin-bound	low		--
panitumumab	min		low
pembrolizumab		min	
pemetrexed		low	
pentostatin	low		--
pertuzumab	min		low

Drug	NCCN ¹	ASCO ²	MASCC/ ESMO ³
pertuzumab/trastuzumab/hyaluronidase	min		--
pixantrone NUS	--		min
polatuzumab vedotin	low	min	--
pralatrexate	low		min
ramucirumab		min	--
retifanlimab	min		--
rituximab (Riabni , Rituxan , Ruxience , Truxima)		min	
rituximab/hyaluronidase	min		--
romidepsin		mod	
sacituzumab govitecan	high		--
siltuximab	min		--
sirolimus nanoparticle albumin-bound	min		--
streptozocin		high	
tafasitamab	low		--
tagraxofusp		low	--
talimogene laherparepvec	low		--
tebentafusp	low		--
teclistamab	min		--
temozolomide		mod	
temsirrolimus	min		low
thiotepa	low		mod
tisagenlecleucel		low ⁵	--
tisotumab vedotin	low		--
topotecan		low	
trabectedin		mod ⁴	
trastuzumab (Herceptin , Herzuma , Kanjinti , Ogivri , Ontruzant , Trazimera)		min	
trastuzumab/hyaluronidase	min		--
tremelimumab	min		--
triptorelin	min		--
valrubicin	min		--

Drug	NCCN ¹	ASCO ²	MASCC/ ESMO ³
vinblastine		min	
vincristine		min	
vincristine liposomal	min		--
vinflunine NUS	--		low
vinorelbine		min	
ziv-aflibercept		low	

¹ **NCCN 2023.** National Comprehensive Cancer Network. Antiemesis (Version 1.2024). December 13, 2023. [Accessed December 20, 2023](#)

- Continuous infusion may decrease emetic potential.
- For some low-emetic-risk agents, factors related to dosing (particularly continuous dosing) and clinical experience suggest routine premedication is *not* required. An individualized approach is appropriate for whether to premedicate each dose or prescribe antiemetics prn.

² **ASCO 2020.** Hesketh PJ, et al. Antiemetics: ASCO Guideline Update. *J Clin Oncol.* 2020. Aug 20;38(24):2782-2797. [PDF](#)

³ **MASCC/ESMO 2016/2019.** Aapro M, et al. 2016 MASCC/ESMO Antiemetic Guideline 2016 With Updates in 2019. Multinational Association of Supportive Care in Cancer. Updated September 2019. Accessed August 25, 2020.

⁴ **NCCN 2023.** May be highly emetogenic in certain pts.

⁵ **NCCN 2023.** Avoid corticosteroid antiemetic premedication for 3-5 days prior to and 90 days after CAR T-cell tx. Antiemetic regimens used during lymphodepleting chemo regimens should also employ a corticosteroid-sparing approach to antiemetic ppx.